Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 8/20 | 0.56 |
| ▸ | JAK3 | P52333 | 7/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21170 | 0.90 | IGF1R (0.48) | IGF1RJAK2JAK3PTK2 | |
| SCHEMBL24181 | 0.90 | JAK2 (0.56) | JAK2JAK3PTK2 | |
| SCHEMBL20200 | 0.88 | PTGS2 (0.49) | IGF1RJAK2JAK3PTK2 | |
| SCHEMBL15221135 | 0.86 | JAK2 (0.53) | IGF1RJAK2JAK3PTK2AURKA | |
| SCHEMBL20504 | 0.85 | JAK2 (0.74) | JAK2JAK3PTK2AURKA | |
| SCHEMBL20266 | 0.84 | JAK2 (0.55) | IGF1RJAK2JAK3PTK2AURKA | |
| SCHEMBL20513 | 0.83 | JAK2 (0.55) | JAK2JAK3PTK2AURKAKIT | |
| SCHEMBL21597 | 0.82 | JAK2 (0.59) | JAK2JAK3PTK2AURKA | |
| SCHEMBL20114 | 0.82 | JAK2 (0.66) | JAK2JAK3PTK2AURKASTAT6 | |
| SCHEMBL20495 | 0.81 | TTK (0.57) | JAK2JAK3PTK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | IGF1R 101/4885JAK2 5/4885JAK3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.